Development And License Agreement For Mrna Cancer Vaccine With U.S. Biotech Company
30/07/2025 13:57
July 30 (Reuters) - Dx & Vx Co Ltd 180400.KQ: DX&VX SIGNS USD 220 MILLION CO-DEVELOPMENT AND LICENSE AGREEMENT FOR MRNA CANCER VACCINE WITH U.S. BIOTECH COMPANY DX & VX CO LTD - DX&VX PROJECTS SALES REVENUES COULD EXCEED USD 940 MILLION Source text: ID:nPnc9nlvta Further company coverage: 180400.KQ ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Dx & Vx
See all newsBrief: Coree Announces Discovery Of Microbiome Biomarkers Specific To Diabetes And Obesity Patients
Development And License Agreement For Mrna Cancer Vaccine With U.S. Biotech Company
Brief: Dx&Vx Accelerates Development of Universal COVID-19 Vaccine
Slovenia's parliament commission rejects former prime minister as central bank governor
Brief: Dx & Vx Co Ltd Wins 10.3 Billion Won Order